A股異動 | 雙成藥業連續2日升停 跨界併購半導體資產
雙成藥業(002693.SZ)再度封板升停錄得2連板,報6.31元創4個月新高價,總市值26.17億元。9月10日晚,雙成藥業公吿稱,公司擬收購寧波奧拉半導體股份有限公司100%股份。據悉,奧拉股份的核心收入來源於“芯片產品+IP授權服務”兩大業務板塊。本次交易完成後,上市公司將實現戰略轉型,重點發展模擬芯片及數模混合芯片設計業務,有利於上市公司尋求新的利潤增長點,進一步提高上市公司持續經營能力。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.